MVM

Buchanan & Edwards (BE) Welcomes John Greenhalgh as Chief Financial Officer

Retrieved on: 
Thursday, January 11, 2024
Forecasting, BearingPoint, Accounting, CFO, Knowledge, Octo, Greenhalgh, MVM, University, Business, MBA, James Madison University, Public sector, Smith School of Business, Growth, Management

WASHINGTON, Jan. 11, 2024 /PRNewswire-PRWeb/ -- Buchanan & Edwards Inc. (BE), a recognized leader providing technology and mission services to National Security and Federal Civilian customers, is pleased to announce the appointment of John Greenhalgh as Chief Financial Officer (CFO).

Key Points: 
  • John Greenhalgh joins Buchanan & Edwards (BE) as Chief Financial Officer.
  • WASHINGTON, Jan. 11, 2024 /PRNewswire-PRWeb/ -- Buchanan & Edwards Inc. (BE), a recognized leader providing technology and mission services to National Security and Federal Civilian customers, is pleased to announce the appointment of John Greenhalgh as Chief Financial Officer (CFO).
  • In his role as CFO, John will be a key member of the executive team, leading strategic growth, planning, budgeting and forecasting, capital financing, accounting, contracts, and overall corporate financial management.
  • He is a strategic financial leader who leverages his collaborative leadership style to help transform companies.

Gynesonics Announces $67M Financing to Expand Commercialization of Sonata® Procedure

Retrieved on: 
Thursday, November 2, 2023
Hysterectomy, MVM, General partnership, Uterine fibroid, Woman, Investment, Patient, Acceleration, Pharmaceutical industry

The round was led by existing Gynesonics investors Amzak Health, Endeavour Vision, Kaiser Permanente Ventures, Runway Growth Capital, and Bain Capital; with new investments coming from MVM Partners as well as several other healthcare investors excited about Gynesonics’ commercial advances.

Key Points: 
  • The round was led by existing Gynesonics investors Amzak Health, Endeavour Vision, Kaiser Permanente Ventures, Runway Growth Capital, and Bain Capital; with new investments coming from MVM Partners as well as several other healthcare investors excited about Gynesonics’ commercial advances.
  • “Gynesonics continues to lay a strong foundation for success, having achieved a number of important commercial milestones in the most recent quarters,” said Joyce Erony, General Partner, Amzak Health.
  • “The Company is very well positioned to continue the acceleration of its growth going forward.
  • MVM is glad to support Gynesonics in offering a uterus-preserving, incisionless alternative to hysterectomy and myomectomy.”
    “This funding will enable Gynesonics to continue to expand commercial operations and provide millions of patients suffering from symptomatic fibroids a safe and efficacious minimally invasive treatment,” said Skip Baldino, President and CEO of Gynesonics.

Gynesonics Announces $67M Financing to Expand Commercialization of Sonata® Procedure

Retrieved on: 
Thursday, November 2, 2023
Hysterectomy, MVM, General partnership, Uterine fibroid, Woman, Investment, Patient, Acceleration, Cryptocurrency, Pharmaceutical industry

The round was led by existing Gynesonics investors Amzak Healthcare, Endeavour Vision, Kaiser Permanente Ventures, Runway Growth Capital, and Bain Capital; with new investments coming from MVM Partners as well as several other healthcare investors excited about Gynesonics’ commercial advances.

Key Points: 
  • The round was led by existing Gynesonics investors Amzak Healthcare, Endeavour Vision, Kaiser Permanente Ventures, Runway Growth Capital, and Bain Capital; with new investments coming from MVM Partners as well as several other healthcare investors excited about Gynesonics’ commercial advances.
  • “Gynesonics continues to lay a strong foundation for success, having achieved a number of important commercial milestones in the most recent quarters,” said Joyce Erony, General Partner, Amzak Ventures.
  • “The Company is very well positioned to continue the acceleration of its growth going forward.
  • MVM is glad to support Gynesonics in offering a uterus-preserving, incisionless alternative to hysterectomy and myomectomy.”
    “This funding will enable Gynesonics to continue to expand commercial operations and provide millions of patients suffering from symptomatic fibroids a safe and efficacious minimally invasive treatment,” said Skip Baldino, President and CEO of Gynesonics.

BioProtect Secures $28M to Commercialize its Biodegradable Balloon for Rectal Protection During Prostate Cancer Radiation Therapy

Retrieved on: 
Wednesday, September 27, 2023
Consensus, Radiation, Investment, ASTRO, Toxicity, Patient, FDA, Vincent Tchenguiz, MVM, Society, Medical laboratory scientist, Prostate cancer, Medical device

The round was led by MVM Partners, with participation from current investors: Triventures, KB Investments, Peregrine Ventures, Almeda Ventures, and Consensus Business Group of Vincent Tchenguiz.

Key Points: 
  • The round was led by MVM Partners, with participation from current investors: Triventures, KB Investments, Peregrine Ventures, Almeda Ventures, and Consensus Business Group of Vincent Tchenguiz.
  • Proceeds from this financing will support US commercialization of the BioProtect Balloon Implant System, which recently received FDA clearance for rectal protection during radiation therapy for prostate cancer.
  • "We believe that our balloon has the potential to revolutionize rectal protection from radiation toxicity during prostate cancer radiation therapy," said BioProtect's CEO, Itay Barnea.
  • "To-date, our spacer has been successfully implanted in over 2,000 patients worldwide and has proven to be safe and effective.

EQS-News: JDC Group AG: JDC on a clear growth trajectory in the second quarter of 2023

Retrieved on: 
Thursday, August 10, 2023
Insurance, Bain Capital, Tax, Carbon neutrality, EBIT, CSR, Canada Life, EUR, Advisory, Acquisition, GRI, Guideline, JDC, ISIN, Depreciation, Growth, MVM, Environment, Lithium, Renewable energy, Film industry, Video game, EBITDA

As a result, revenues in the first half of 2023 are up 4.5 percent to EUR 84.6 million (1 HY 2022: EUR 81.0 million).

Key Points: 
  • As a result, revenues in the first half of 2023 are up 4.5 percent to EUR 84.6 million (1 HY 2022: EUR 81.0 million).
  • For the first half of the year, this translates into growth of 11.2 percent to EUR 75.0 million.
  • Through compensation services, the entire JDC Group is already operating completely carbon-neutral as early soon as 2022.
  • The key figures for the first half and the second quarter of 2023 are as follows:

WEMIX and Hub71 partner to grow global blockchain startup ecosystem

Retrieved on: 
Thursday, June 1, 2023
Ethereum, Metaverse, DAO, Partnership, Abu Dhabi Global Market, Decentralized finance, Government, DABS, Digital asset, EVM, Memorandum of understanding, Blockchain, Ecosystem, MVM, Cryptocurrency, Web3, WeMade Entertainment, Growth

Partnership to bring WEMIX's blockchain expertise to Hub71+ Digital Assets specialist ecosystem, and leverages global network of startups and partners

Key Points: 
  • Partnership to bring WEMIX's blockchain expertise to Hub71+ Digital Assets specialist ecosystem, and leverages global network of startups and partners
    SEOUL, South Korea, June 1, 2023 /PRNewswire/ -- Leading Korean blockchain developer WEMIX and Hub71, Abu Dhabi's global tech ecosystem, have signed a memorandum of understanding (MoU) to create and accelerate growth opportunities for their respective portfolio companies and Web3 startups.
  • Elodie Robin Guillerm, Head of Growth and Strategy at Hub71, said: "The addition of WEMIX to our Hub71+ Digital Assets ecosystem is testament to the growth potential there is to be seized from Abu Dhabi.
  • The first Hub71+ to launch is 'Hub71+ Digital Assets' – focused on unleashing the disruptive potential of Web3 and the growth of digital assets.
  • Hub71+ Digital Assets is based at Hub71 in Abu Dhabi Global Market (ADGM) where Web3 startups can operate in a progressive regulatory environment, which offers world-class blockchain and virtual asset infrastructure.

Hungarian Leading Energy Company, MVM Group's Employee Knowledge Centre has been Renewed by Grape Solutions

Retrieved on: 
Tuesday, March 14, 2023
Knowledge, Research, MVM Group, Indigenous Knowledge Centre, MVM, Communication, CEE, Knowledge management

MVM Group is the most prominent player in the Hungarian energy sector, the second largest enterprise in Hungary and the tenth largest in the CEE region.

Key Points: 
  • MVM Group is the most prominent player in the Hungarian energy sector, the second largest enterprise in Hungary and the tenth largest in the CEE region.
  • The MVM Knowledge Centre was established and is operated by the Technology Innovation Directorate (TIIG) with the support of the Knowledge Centre Working Group.
  • Its primary task is to provide a tool for the three pillars of knowledge management: knowledge creation, knowledge transfer and knowledge exploitation.
  • "We have been planning to significantly redesign the MVM Knowledge Centre platform for the 18 000 employees of MVM Group.

MDxHealth Shareholder Transparency Declarations

Retrieved on: 
Friday, March 3, 2023
Radium, FSMA, Brussels Stock Exchange, Disclosure, Article, Financial Services and Markets Authority (Belgium), Financial services, LLP, Transparency, RMM, MVM, Furthering Asbestos Claims Transparency Act of 2015, Robin, Person, Exercise, Security (finance)

The Company was notified that the number of shares with respect to which MVM Partners, LLC can exercise voting rights passively crossed below the threshold of 20% of the outstanding shares and voting rights of mdxhealth on February 7, 2023.

Key Points: 
  • The Company was notified that the number of shares with respect to which MVM Partners, LLC can exercise voting rights passively crossed below the threshold of 20% of the outstanding shares and voting rights of mdxhealth on February 7, 2023.
  • Notably, it follows from the notification by MVM Partners, LLC, who notified alone, that an aggregate of 45,504,584 shares of mdxhealth, representing 17.31% of the 262,880,936 outstanding shares and voting rights of mdxhealth, is held through the following entities: MVM V LP (which owns 1,877,945 American depositary shares ("ADSs") and 25,805,845 shares of mdxhealth) and MVM GP (No.
  • 5) LP (which owns 38,721 ADSs and 532,079 shares of mdxhealth).
  • Notably, it follows from the notification by Biovest NV that 11,923,587 shares of mdxhealth, representing 4.54% of the 262,880,936 outstanding shares and voting rights of mdxhealth, are held through Biovest NV.

Open Systems Redefines MDR Market with Launch of Ontinue

Retrieved on: 
Tuesday, February 14, 2023
Software, Networks, Internet, Artificial Intelligence, Data Management, Technology, Other Technology, Security, Sentinel, Organization, Automation, ROI, MDR, Microsoft Teams, Executive, MSSP, MDE, Noise, Acquisition, MVM, Defender, Microsoft, Tier 2, Secop, System, Collaboration, Collateral damage, ION, Risk, Intelligence, Doctor of Philosophy, Learning, Microsoft Defender Antivirus, Environment, Overalls, Social media, Specialization, Tier 3, Video game, Risk management, Mobile phone, SIEM, Command & Conquer

Open Systems, a leading cybersecurity and networking provider for the enterprise cloud, today has redefined the managed detection and response (MDR) market with the launch of Ontinue, its new MDR division.

Key Points: 
  • Open Systems, a leading cybersecurity and networking provider for the enterprise cloud, today has redefined the managed detection and response (MDR) market with the launch of Ontinue, its new MDR division.
  • ​Unlike other MDR services available today, Ontinue’s newly launched MXDR service, Ontinue ION, delivers Nonstop SecOps with 24/7, always-on protection.
  • “Ontinue is upending the MDR market by redefining what MDR services are capable of.
  • This is what the Ontinue ION platform delivers to customers – nonstop,” said Geoff Haydon, the Executive Chairman of Open Systems and CEO of Ontinue.

LexaGene Provides Update on BioPharma Sector

Retrieved on: 
Wednesday, February 8, 2023
Area studies, RNA, Genetic testing, Minute virus of mice, Advertising, R, CDMO, LXG, Vesivirus, MVM, DC, Common, Escherichia coli, OTCQB, Mycoplasma, Partnership, Organization, Bacteria, Vaccine, Cryptocurrency, Fine chemical, Mouse

Dr. Jack Regan, CEO and Founder of LexaGene commented, “We continue to work with both of our biopharma customers - a more traditional biopharma company with a market cap that is >$100B and a leading Contract Drug Manufacturing Organization (CDMO) with a market cap that is >$40B.

Key Points: 
  • Dr. Jack Regan, CEO and Founder of LexaGene commented, “We continue to work with both of our biopharma customers - a more traditional biopharma company with a market cap that is >$100B and a leading Contract Drug Manufacturing Organization (CDMO) with a market cap that is >$40B.
  • During our conversations with our traditional biopharma customer, they suggested presenting at the 2023 National Institute for Innovation in Manufacturing Biopharmaceuticals (“NIIMBL”) National Meeting being held in June in Washington, DC.
  • NIIMBL is a public-private partnership whose mission is to accelerate biopharmaceutical innovation and advance other industry objectives.
  • This exposure will help LexaGene achieve better brand awareness and wider adoption in the industry.”
    For more information about LexaGene and the MiQLab System, please visit www.lexagene.com or follow us on Twitter and LinkedIn .